We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

123 hedge funds and large institutions have $399M invested in Keryx Biopharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

13% more capital invested

Capital invested by funds: $354M → $399M (+$44.8M)

6% more funds holding

Funds holding: 116123 (+7)

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

30% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $4.37M

Holders
123
Holders Change
+7
Holders Change %
+6.03%
% of All Funds
3.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
36
Reduced
38
Closed
12
Calls
$3.06M
Puts
$4.37M
Net Calls
-$1.31M
Net Calls Change
-$776K
Name Holding Trade Value Shares
Change
Change in
Stake
Creative Planning
76
Creative Planning
Kansas
$215K -$273 -50 -0.1%
Public Employees Retirement Association of Colorado
77
Public Employees Retirement Association of Colorado
Colorado
$189K
VOYA Investment Management
78
VOYA Investment Management
Georgia
$178K -$48.8K -8,931 -23%
Stifel Financial
79
Stifel Financial
Missouri
$178K +$165K +30,258 New
PHS
80
Pekin Hardy Strauss
Illinois
$176K
LCC
81
Lincoln Capital Corp
Rhode Island
$158K +$146K +26,800 New
CWG
82
C WorldWide Group
Denmark
$152K -$2.68M -490,110 -95%
Legal & General Group
83
Legal & General Group
United Kingdom
$151K +$14.4K +2,632 +11%
SGCA
84
Steel Grove Capital Advisors
Tennessee
$149K
VKH
85
Virtu KCG Holdings
New York
$140K -$82.4K -15,079 -39%
Citigroup
86
Citigroup
New York
$131K +$2.68K +491 +2%
Invesco
87
Invesco
Georgia
$120K -$1.14M -207,945 -91%
DAM
88
Deltec Asset Management
New York
$117K
ST
89
Spot Trading
Illinois
$115K +$8.76K +1,603 +9%
SC
90
Sculptor Capital
New York
$104K
Principal Financial Group
91
Principal Financial Group
Iowa
$83K
HSBC Holdings
92
HSBC Holdings
United Kingdom
$80K +$74.3K +13,600 New
ProShare Advisors
93
ProShare Advisors
Maryland
$74K +$69.3K +12,682 New
RJA
94
Raymond James & Associates
Florida
$70K -$13.9K -2,537 -18%
AG
95
Aperio Group
California
$67K +$2.2K +403 +4%
SBIA
96
Sheaff Brock Investment Advisors
Indiana
$67K +$8.2K +1,500 +15%
LPL Financial
97
LPL Financial
California
$66K +$59K +10,792 New
Commonwealth Equity Services
98
Commonwealth Equity Services
Massachusetts
$63K
FRM
99
Fox Run Management
Connecticut
$62K +$57.9K +10,600 New
Canada Life
100
Canada Life
Manitoba, Canada
$59K

KERX Hedge Fund Activity: Q4 2016 in Review

123 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2016, worth a combined $399M — up 13% from $354M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KERX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 38 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $7.06M. The largest seller was Fidelity Investments, cutting an estimated $3.82M.

  • 123 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2016, up from 116 in Q3 2016.
  • Funds reported $399M of Keryx Biopharmaceuticals Inc stock for Q4 2016, up 13% quarter-over-quarter.
  • 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2016 and 12 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q4 2016 was Deerfield Management, an estimated $7.06M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2016.